Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

The Rate of Venous Thromboembolism in Cancer Patients Varies By Khorana Risk Category

Alok A. Khorana, MD, Nicole M. Kuderer, MD, Keith R. McCrae, MD, Dejan Milentijevic, PhD, Guillaume Germain, MA, François Laliberté, MA, Nguyen Le, BSc, Patrick Lefebvre, MA, Gary H. Lyman, MD MPH, FRCP, Michael B. Streiff, MD

Blood (2018) 132 (Supplement 1): 3798.

https://doi.org/10.1182/blood-2018-99-116224

Published: 2018

Journal Articles

Healthcare Costs in Patients with Cancer Increase with Increasing Risk of Venous Thromboembolism

Michael B. Streiff, MD, Keith R. McCrae, MD, Nicole M. Kuderer, MD, Dejan Milentijevic, PhD, Guillaume Germain, MA, François Laliberté, MA, Nguyen Le, BSc, Patrick Lefebvre, MA, Gary H. Lyman, MD MPH, FRCP, Alok A. Khorana, MD

Blood (2018) 132 (Supplement 1): 3799.

https://doi.org/10.1182/blood-2018-99-117121

Published: 2018

Journal Articles

Front-Line Ibrutinib Treatment Is Associated with Longer Time to Next Treatment, Net Total Cost Reduction, and Lower Healthcare Resource Utilization Compared to Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia

Song Wang, PhD, Bruno Emond, MSc, Hela Romdhani, PhD, Patrick Lefebvre, MA, Murali Sundaram, MBA, PhD, Anthony R Mato, MD

Blood (2018) 132 (Supplement 1): 2306.

https://doi.org/10.1182/blood-2018-99-116473

Published: 2018

Journal Articles

Treatment Patterns of Hypomethylating Agents in Older (≥65 Years) Acute Myeloid Leukemia Patients Who Did Not Receive Intensive Chemotherapy: A Retrospective Claims Database Analysis

Murali Sundaram, MBA, PhD, Marie-Hélène Lafeuille, MA, Daniela Hoehn, MDPhD, Bruno Emond, MSc, Hela Romdhani, PhD, Patrick Lefebvre, MA

Blood (2017) 130 (Supplement 1): 5600.

https://doi.org/10.1182/blood.V130.Suppl_1.5600.5600

Published: 2017

Journal Articles

Healthcare Cost Impact of Continued Anticoagulation Therapy with Rivaroxaban Versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the Einstein Choice Trial Population

Bruce L. Davidson, MD MPH, Philip S. Wells, MD FRCPC, MSc, Martin H. Prins, MD PhD, Jan Beyer-Westendorf, MD, Anthonie WA. Lensing, MD PhD, Lloyd Haskell, MD, Bennett Levitan, MD PhD, François Laliberté, Veronica Ashton, MPH, Yongling Xiao, PhD, Dominique Lejeune, Concetta Crivera, Patrick Lefebvre, MA, Qi Zhao, MPH, Zhong Yuan, MD PhD, Jeff Schein, Paolo Prandoni, MD PhD

Blood (2017) 130 (Supplement 1): 218.

https://doi.org/10.1182/blood.V130.Suppl_1.218.218

Published: 2017

Journal Articles

VTE Recurrence and Safety of Anticoagulants Among Patients with Cancer Treated for Venous Thromboembolism

Alok A. Khorana, MD, Keith McCrae, MD, Dejan Milentijevic, Nora McCormick, François Laliberté, Concetta Crivera, Patrick Lefebvre, MA, Dominique Lejeune, Heather Rozjabek, Jeff Schein, Michael B. Streiff

Blood (2017) 130 (Supplement 1): 4631.

https://doi.org/10.1182/blood.V130.Suppl_1.4631.4631

Published: 2017

Journal Articles

Managing Acute Myeloid Leukemia in Older Patients: Are We Making Progress? An Analysis of Treatment Patterns and Healthcare Resource Utilization

Marie-Hélène Lafeuille, MA, Murali Sundaram, MBA, PhD, Daniela Hoehn, MDPhD, Bruno Emond, MSc, Hela Romdhani, PhD, Patrick Lefebvre, MA

Blood (2017) 130 (Supplement 1): 4714.

https://doi.org/10.1182/blood.V130.Suppl_1.4714.4714

Published: 2017

Journal Articles

Healthcare Costs Associated with Venous Thromboembolism in Cancer Patients Treated with Anticoagulants

Michael B. Streiff, Keith McCrae, MD, Dejan Milentijevic, Nora McCormick, François Laliberté, Concetta Crivera, Patrick Lefebvre, MA, Dominique Lejeune, Heather Rozjabek, Jeff Schein, Alok A. Khorana, MD

Blood (2017) 130 (Supplement 1): 4640.

https://doi.org/10.1182/blood.V130.Suppl_1.4640.4640

Published: 2017

Journal Articles

Risk of Venous Thromboembolism Recurrence Among Rivaroxaban Treated Patients Who Continued Versus Discontinued Therapy: Analyses Among VTE Patients

Alok A. Khorana, MD, Jeffrey S Berger, MD, Philip S Wells, MD, Roger Seheult, MD, Veronica Ashton, MPH, François Laliberté, MA, Concetta Crivera, PharmD, MPH, Dominique Lejeune, MA, Jeff Schein, DrPH, MPH, Peter Wildgoose, PhD, Patrick Lefebvre, MA, Scott Kaatz, DO, MSc

Blood (2016) 128 (22): 144.

https://doi.org/10.1182/blood.V128.22.144.144

Published: 2016

Journal Articles

Safety of Anticoagulant Therapies for Treatment of Venous Thromboembolism in Patients with Cancer

Michael Streiff, MD, Dejan Milentijevic, Keith McCrae, Daniel Yannicelli, Jonathan Fortier, Winnie Nelson, François Laliberté, MA, Concetta Crivera, PharmD, MPH, Patrick Lefebvre, MA, Jeff Schein, DrPH, MPH, Alok A. Khorana, MD

Blood (2016) 128 (22): 1178.

https://doi.org/10.1182/blood.V128.22.1178.1178

Published: 2016

Journal Articles

VTE-Related Healthcare Resource Utilization and Costs Associated with Venous Thromboembolism in Cancer Patients Treated with Anticoagulants

Michael Streiff, MD, Dejan Milentijevic, Keith R. McCrae, MD, Jonathan Fortier, François Laliberté, MA, Patrick Lefebvre, MA, Jeff Schein, DrPH, MPH, Alok A. Khorana, MD

Blood (2016) 128 (22): 3524.

https://doi.org/10.1182/blood.V128.22.3524.3524

Published: 2016

Journal Articles

Healthcare Resource Utilization and Costs Associated with Venous Thromboembolism Recurrence in Patients with Cancer

Alok A. Khorana, MD, Keith R. McCrae, MD, Dejan Milentijevic, Jonathan Fortier, François Laliberté, MA, Concetta Crivera, PharmD, MPH, Patrick Lefebvre, MA, Jeff Schein, DrPH, MPH

Blood (2016) 128 (22): 4734.

https://doi.org/10.1182/blood.V128.22.4734.4734

Published: 2016

Journal Articles

Comparable Outcomes With Bortezomib-Cyclophosphamide-Dexamethasone (VCD) and Bortezomib-Lenalidomide-Dexamethasone (VRD) For Initial Treatment Of Newly Diagnosed Multiple Myeloma (MM)

Blood (2013) 122 (21): 3178.

https://doi.org/10.1182/blood.V122.21.3178.3178

Published: 2013

Journal Articles

Meta-Analysis of the Efficacy and Safety of Bortezomib Retreatment in Patients with Multiple Myeloma (MM)

Kevin B Knopf, MD, Mei Sheng Duh, ScD, MPH, Marie-Hélène Lafeuille, MA, Jonathan Gravel, Patrick Lefebvre, MA, Liviu Niculescu, Abbie Ba-Mancini, BS, MBA, Esprit Ma, Hongliang Shi, MS, Raymond L. Comenzo, MD

Blood (2012) 120 (21): 1863.

https://doi.org/10.1182/blood.V120.21.1863.1863

Published: 2012

Journal Articles

Preoperative Hemoglobin Levels, Characteristics, and Resource Utilization in Total Hip Replacement Patients with An Anemia Diagnosis Versus without An Anemia Diagnosis: An Electronic Medical Record Analysis

Jamie B. Forlenza, PharmD, MS, Lorie Ellis, PhD, Helene Parise, MA, Marie-Hélène Lafeuille, MA, Patrick Lefebvre, MA

Blood (2011) 118 (21): 4748.

https://doi.org/10.1182/blood.V118.21.4748.4748

Published: 2011

Journal Articles

Preoperative Hemoglobin Levels, Characteristics, and Resource Utilization in Total Knee Replacement Patients with An Anemia Diagnosis Versus without An Anemia Diagnosis: An Electronic Medical Record Analysis

Jamie B. Forlenza, PharmD, MS, Lorie Ellis, PhD, Helene Parise, MA, Marie-Hélène Lafeuille, MA, Patrick Lefebvre, MA

Blood (2011) 118 (21): 2089.

https://doi.org/10.1182/blood.V118.21.2089.2089

Published: 2011

Journal Articles

Higher Erythroid Response Rates with Epoetin Alfa Versus Other Agents in Treatment-Naïve Low/Int-1 Myelodysplastic Syndrome Patients: A Comparative Meta-Analysis

Suneel Mundle, PhD, Patrick Lefebvre, MA, Francis Vekeman, MA, Mei Sheng Duh, MPH, ScD, François Laliberté, MA, Ruchi Rastogi, PharmD, Victor Moyo, MD

Blood (2008) 112 (11): 5074.

https://doi.org/10.1182/blood.V112.11.5074.5074

Published: 2008

Journal Articles

Comparison of Epoetin Alfa and Darbepoetin Alfa Dosing and Costs in an Inpatient Population with Myelodysplastic Syndromes

Marie- Hélène Lafeuille, BA, Francis Vekeman, MA, Robert A. Bailey, MD, R. Scott Mckenzie, MD, Patrick Lefebvre, MA

Blood (2008) 112 (11): 1297.

https://doi.org/10.1182/blood.V112.11.1297.1297

Published: 2008

Journal Articles

Treatment of MDS Related Transfusion-Dependent Anemia with Epoetin alfa: A Meta-Analysis Perspective.

Suneel Mundle, PhD, Patrick Lefebvre, MA, Mei S. Duh, ScD, MPH, Francis Vekeman, MA, Behin Yektashenas, PharmD, Francois Laliberté, MA, Victor Moyo, MD

Blood (2007) 110 (11): 1471.

https://doi.org/10.1182/blood.V110.11.1471.1471

Published: 2007

Journal Articles

Drug Utilization and Cost Considerations of Erythropoiesis-Stimulating Agents in Patients with Myelodysplastic Syndromes.

François Laliberté, MA, Scott R. McKenzie, MD, Brahim K. Bookhart, MBA, MPH, Mei S. Duh, ScD, MPH, Patrick Lefebvre, MA

Blood (2007) 110 (11): 4611.

https://doi.org/10.1182/blood.V110.11.4611.4611

Published: 2007

NARROW

The Rate of Venous Thromboembolism in Cancer Patients Varies By Khorana Risk Category

Healthcare Costs in Patients with Cancer Increase with Increasing Risk of Venous Thromboembolism

Front-Line Ibrutinib Treatment Is Associated with Longer Time to Next Treatment, Net Total Cost Reduction, and Lower Healthcare Resource Utilization Compared to Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia

Treatment Patterns of Hypomethylating Agents in Older (≥65 Years) Acute Myeloid Leukemia Patients Who Did Not Receive Intensive Chemotherapy: A Retrospective Claims Database Analysis

Healthcare Cost Impact of Continued Anticoagulation Therapy with Rivaroxaban Versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the Einstein Choice Trial Population

VTE Recurrence and Safety of Anticoagulants Among Patients with Cancer Treated for Venous Thromboembolism

Managing Acute Myeloid Leukemia in Older Patients: Are We Making Progress? An Analysis of Treatment Patterns and Healthcare Resource Utilization

Healthcare Costs Associated with Venous Thromboembolism in Cancer Patients Treated with Anticoagulants

Risk of Venous Thromboembolism Recurrence Among Rivaroxaban Treated Patients Who Continued Versus Discontinued Therapy: Analyses Among VTE Patients

Safety of Anticoagulant Therapies for Treatment of Venous Thromboembolism in Patients with Cancer

VTE-Related Healthcare Resource Utilization and Costs Associated with Venous Thromboembolism in Cancer Patients Treated with Anticoagulants

Healthcare Resource Utilization and Costs Associated with Venous Thromboembolism Recurrence in Patients with Cancer

Comparable Outcomes With Bortezomib-Cyclophosphamide-Dexamethasone (VCD) and Bortezomib-Lenalidomide-Dexamethasone (VRD) For Initial Treatment Of Newly Diagnosed Multiple Myeloma (MM)

Meta-Analysis of the Efficacy and Safety of Bortezomib Retreatment in Patients with Multiple Myeloma (MM)

Preoperative Hemoglobin Levels, Characteristics, and Resource Utilization in Total Hip Replacement Patients with An Anemia Diagnosis Versus without An Anemia Diagnosis: An Electronic Medical Record Analysis

Preoperative Hemoglobin Levels, Characteristics, and Resource Utilization in Total Knee Replacement Patients with An Anemia Diagnosis Versus without An Anemia Diagnosis: An Electronic Medical Record Analysis

Higher Erythroid Response Rates with Epoetin Alfa Versus Other Agents in Treatment-Naïve Low/Int-1 Myelodysplastic Syndrome Patients: A Comparative Meta-Analysis

Comparison of Epoetin Alfa and Darbepoetin Alfa Dosing and Costs in an Inpatient Population with Myelodysplastic Syndromes

Treatment of MDS Related Transfusion-Dependent Anemia with Epoetin alfa: A Meta-Analysis Perspective.

Drug Utilization and Cost Considerations of Erythropoiesis-Stimulating Agents in Patients with Myelodysplastic Syndromes.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only